Receptor Binding Domain Based HIV Vaccines

Receptor Binding Domain Based HIV Vaccines

This paper analyzes the main trend of the development of acquired immunodeficiency syndrome (AIDS) vaccines in recent years. Designing an HIV-1 vaccine that provides robust protection from HIV-1 infection remains a challenge despite many years of effort. Therefore, we describe the receptor binding d...

Full description

Bibliographic Details
Main Authors: Huan Liu, Wenwen Bi, Qian Wang, Lu Lu, Shibo Jiang
Format: Article
Language:English
Published: Hindawi Limited 2015-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2015/594109
id doaj-c7c8b2a868564288b60b02373a3a7f1b
record_format Article
spelling doaj-c7c8b2a868564288b60b02373a3a7f1b2020-11-24T21:27:48ZengHindawi LimitedBioMed Research International2314-61332314-61412015-01-01201510.1155/2015/594109594109Receptor Binding Domain Based HIV VaccinesHuan Liu0Wenwen Bi1Qian Wang2Lu Lu3Shibo Jiang4State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Xiaohongshan 44, Wuhan 430071, ChinaKey Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Road, Xuhui District, Shanghai 200032, ChinaKey Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Road, Xuhui District, Shanghai 200032, ChinaKey Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Road, Xuhui District, Shanghai 200032, ChinaKey Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Road, Xuhui District, Shanghai 200032, ChinaThis paper analyzes the main trend of the development of acquired immunodeficiency syndrome (AIDS) vaccines in recent years. Designing an HIV-1 vaccine that provides robust protection from HIV-1 infection remains a challenge despite many years of effort. Therefore, we describe the receptor binding domain of gp120 as a target for developing AIDS vaccines. And we recommend some measures that could induce efficiently and produce cross-reactive neutralizing antibodies with high binding affinity. Those measures may offer a new way of the research and development of the potent and broad AIDS vaccines.http://dx.doi.org/10.1155/2015/594109
collection DOAJ
language English
format Article
sources DOAJ
author Huan Liu
Wenwen Bi
Qian Wang
Lu Lu
Shibo Jiang
spellingShingle Huan Liu
Wenwen Bi
Qian Wang
Lu Lu
Shibo Jiang
Receptor Binding Domain Based HIV Vaccines
BioMed Research International
author_facet Huan Liu
Wenwen Bi
Qian Wang
Lu Lu
Shibo Jiang
author_sort Huan Liu
title Receptor Binding Domain Based HIV Vaccines
title_short Receptor Binding Domain Based HIV Vaccines
title_full Receptor Binding Domain Based HIV Vaccines
title_fullStr Receptor Binding Domain Based HIV Vaccines
title_full_unstemmed Receptor Binding Domain Based HIV Vaccines
title_sort receptor binding domain based hiv vaccines
publisher Hindawi Limited
series BioMed Research International
issn 2314-6133
2314-6141
publishDate 2015-01-01
description This paper analyzes the main trend of the development of acquired immunodeficiency syndrome (AIDS) vaccines in recent years. Designing an HIV-1 vaccine that provides robust protection from HIV-1 infection remains a challenge despite many years of effort. Therefore, we describe the receptor binding domain of gp120 as a target for developing AIDS vaccines. And we recommend some measures that could induce efficiently and produce cross-reactive neutralizing antibodies with high binding affinity. Those measures may offer a new way of the research and development of the potent and broad AIDS vaccines.
url http://dx.doi.org/10.1155/2015/594109
work_keys_str_mv AT huanliu receptorbindingdomainbasedhivvaccines
AT wenwenbi receptorbindingdomainbasedhivvaccines
AT qianwang receptorbindingdomainbasedhivvaccines
AT lulu receptorbindingdomainbasedhivvaccines
AT shibojiang receptorbindingdomainbasedhivvaccines
_version_ 1725973317607751680

Similar Items